Medicare change-of-heart over ICD data
This article was originally published in The Gray Sheet
Executive Summary
CMS will not seek access to interim data from NIH's Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT), despite earlier plans to meet with agency to determine why the study's data safety monitoring board opted to allow patients to continue in the placebo arm (1"The Gray Sheet" March 31, 2003, p. 3). According to the Centers for Medicare & Medicaid Services, access to the interim data would jeopardize the blinded nature of the study and ultimately would be less relevant than the trial's complete results, expected by 2004. CMS instead will try to achieve detailed knowledge of SCD-HeFT patient characteristics and learn from NIH which factors led the DSMB to make its decision...
You may also be interested in...
Tunis Presses NIH To Share ICD Study Findings; Dollens Claims Data Irrelevant
CMS will contact the National Heart, Lung & Blood Institute within the next two weeks to try to determine why SCD-HeFT study patients who met the MADIT-II trial criteria were not switched to the active ICD treatment arm
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.